EMGTEarly Manifest Glaucoma Trial
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
In the EMGT, the magnitude of initial IOP reduction was a major factor influencing outcome [46].
Our observations of different phases of association between VRQL and BEMD are supported by the results from a twenty-year follow-up of patients in the EMGT [33].
The EMGT reported that the mean rate of visual field defect progression in untreated NTG patients was 0.36 dB/year [8].
In the EMGT [8], risk decreased by approximately 10% with each mmHg of IOP reduction from baseline.
In the large CNTGS and EMGT cohort studies, progression of the visual field defect was significantly inhibited when the intraocular pressure was reduced by 25-30% [19, 20].
For the primary outcome of VF and/or ONH stereophotograph progression, given the number of TCA stable and TCA-progressed eyes at enrollment and assuming an annual progression rate of 0.08 in the TCA stable group (similar to EMGT) [26], the smallest hazard ratio that could be detected with at least 80% power (at [alpha] = 0.05 by 2-tailed test) was 3.3.
The EMGT criterion for VF progression was recently shown to have high specificity [28].